Web Exclusive

Sarcomas, a group of malignant tumors that develop in soft tissue and bone, can affect any part of the body but most often occur in the abdomen, arms, and legs. Soft-tissue sarcomas typically form in the muscle, cartilage, fat, blood vessels, nerves, and other connective or supportive tissues, including the tendons and joint linings.
In the United States, an estimated 30 million individuals have an eating disorder. Associated with the highest mortality rate of all mental illnesses, eating disorders claim the lives of nearly 20% of those affected.
A critical part of care planning for patients with cancer is the prevention and management of chemotherapy-induced nausea and vomiting (CINV), one of the most feared side effects of chemotherapy.
Lung cancer, melanoma, and renal-cell carcinoma represent significant burdens for patients and for the healthcare system. In light of the high morbidity and mortality associated with these malignancies and the quality-of-life challenges, there is a marked need for additional therapeutic options that improve outcomes for patients with melanoma, non–small-cell lung cancer (NSCLC), or renal-cell carcinoma.
Basal-cell carcinoma is the most common type of skin cancer, accounting for approximately 80% of nonmelanoma skin cancers. More than 2.8 million new cases of basal-cell carcinoma are diagnosed annually in the United States, and 3000 people die from this disease annually.
Lung cancer is one of the most common types of cancer in the United States—second only to breast cancer. An estimated 221,200 new cases of lung cancer were diagnosed in 2015 alone, representing 13.3% of all new cancer cases.
Colorectal cancer (CRC) is a major health problem, with high financial and personal costs. CRC is the third most common cancer in the United States, and is the second leading cause of US cancer death.
Chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL) are common hematologic malignancies that represent a significant burden to patients and to the healthcare system. In light of the morbidity, mortality, and quality-of-life challenges associated with CLL and NHL, there is a marked need for additional therapeutic options for patients with these malignancies.
Lung cancer is the second most common cancer in the United States. In 2015, an estimated 221,200 new cases of lung cancer were diagnosed, representing 13.3% of all new cancer cases.
Page 3 of 7
Results 21 - 30 of 68
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME